SCHEMBL6495504

SCHEMBL6495504

COc1ccc(-c2cc3ncnn3c(O)n2)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.54
ALDH1A1 P00352 5/20 0.54
HPGD P15428 5/20 0.54
NPSR1 Q6W5P4 1/20 0.54
FYN P06241 7/20 0.48
PIK3CG P48736 1/20 0.47
HSD17B10 Q99714 4/20 0.47
TSHR P16473 3/20 0.47
MAPK1 P28482 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HTT P42858 2/20 0.47
USP2 O75604 1/20 0.47
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 3/20 0.45
TP53 P04637 3/20 0.45
FUBP1 Q96AE4 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6507335 0.76 SYK (0.58) KDM4EALDH1A1HPGDFYNPIK3CG
SCHEMBL16784809 0.74 EGLN2 (0.38) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL9143870 0.72 PIK3CG (0.67) KDM4EALDH1A1HPGDFYNPIK3CG
SCHEMBL6508697 0.71 SYK (0.71) KDM4EALDH1A1HPGDNPSR1HSD17B10
SCHEMBL17145111 0.67 ALDH1A1 (0.61) KDM4EALDH1A1HPGDFYNHSD17B10
SCHEMBL29792816 0.67 FYN (0.57) KDM4EALDH1A1HPGDFYNHSD17B10
SCHEMBL12953045 0.67 PIK3CG (0.67) KDM4EALDH1A1HPGDFYNPIK3CG
SCHEMBL9219353 0.66 MAPT (0.56) KDM4EALDH1A1FYNPIK3CGMEN1
SCHEMBL6495343 0.66 SYK (0.55) KDM4EALDH1A1HPGDFYNPIK3CG
SCHEMBL29135622 0.65 MEN1 (0.79) KDM4EALDH1A1HPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911443-B2 Imidazopyrimidine derivatives and triazolopyrimidine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-06-28 US disclosed
EP-1278750-B1 IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-08-04 EP disclosed
US-20040054179-A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040054179-A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives XRCC6, XRN2, HRH2 KDM4E 1134/4885ALDH1A1 2402/4885HPGD 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.